Proactiveinvestors Australia CannPal Animal Therapeutics Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia CannPal Animal Therapeutics Ltd RSS feed en Tue, 18 Jun 2019 02:48:34 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - CannPal Animal Therapeutics major shareholder increases stake ]]> https://www.proactiveinvestors.com.au/companies/news/220542/cannpal-animal-therapeutics-major-shareholder-increases-stake-220542.html CannPal Animal Therapeutics Ltd (ASX:CP1) has had one of its major shareholders, Merchant Funds Management, increase its stake to 19.61% from 18.61%.

The increase was the result of a series of on-market trades, the most recent being the purchase of 1 million shares last Thursday 16 May for $145,478.

Merchant is a boutique Perth-based fund manager focused on early-stage ASX opportunities.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The buying activity from Merchant follows purchases from a number of CannPal board members.

The most recent purchase was from founder and managing director Layton Mills who purchased 65,000 shares via on-market trades earlier this month.

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

]]>
Mon, 20 May 2019 08:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220542/cannpal-animal-therapeutics-major-shareholder-increases-stake-220542.html
<![CDATA[News - CannPal Animal Therapeutics managing director buys more shares on-market ]]> https://www.proactiveinvestors.com.au/companies/news/220079/cannpal-animal-therapeutics-managing-director-buys-more-shares-on-market-220079.html CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills has purchased 65,000 shares in the company via on-market trades.

The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

]]>
Mon, 13 May 2019 08:33:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220079/cannpal-animal-therapeutics-managing-director-buys-more-shares-on-market-220079.html
<![CDATA[News - CannPal Animal Therapeutics files new patent application as industry-leading research is recognised ]]> https://www.proactiveinvestors.com.au/companies/news/219703/cannpal-animal-therapeutics-files-new-patent-application-as-industry-leading-research-is-recognised-219703.html CannPal Animal Therapeutics Ltd (ASX:CP1) continues to demonstrate its leading position in developing unique cannabinoid-based treatment for companion animals by filing a further provisional patent application.

This application, which incorporates results of CannPal’s ongoing research, relates to CPAT-01, the company’s lead drug candidate in development for pain and inflammation control in dogs.

Strengthening company’s IP

The invention relates to a composition comprising a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD).

It builds on an earlier filed provisional patent application for the CPAT-01 formulation and seeks to further strengthen CannPal’s Intellectual Property (IP).

READ: CannPal Animal Therapeutics R&D research to be published in leading veterinary journal

The filing comes hot on the heels of recognition of the company’s extensive research at the 2019 AVA Innovation, Research and Development Symposium in Perth yesterday.

Run by the Australian Veterinary Association, it is Australia’s largest veterinary conference and attracted around 1,400 veterinarians.

CannPal’s head of R&D Dr Margaret Curtis presented on the company’s phase I research results for CPAT-01.

Study results presented

She presented on the pharmacokinetic, safety, gene expression and inflammatory biomarker results from CannPal’s robust randomised three group parallel pharmacokinetic study completed in 2018 for CPAT-01.

Dr Curtis said: “The Innovation Symposium was a fantastic opportunity to showcase the breadth and depth of CannPal’s research to the veterinary fraternity in Australia.

“It was a pleasure to share some of the exciting data that CannPal is generating with the wider scientific community, which we believe can help contribute to the advancement of cannabinoid-derived therapeutic research across all species.”

The research abstract will also reach more than 5,000 through publication in Australia’s premier veterinary scientific journal, the Australian Veterinary Journal.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

CannPal’s founder and managing director Layton Mills said that the presentation and AVJ publication were significant milestones.

“There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.

“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines.

“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”

]]>
Mon, 06 May 2019 13:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219703/cannpal-animal-therapeutics-files-new-patent-application-as-industry-leading-research-is-recognised-219703.html
<![CDATA[News - CannPal Animal Therapeutics R&D research to be published in leading veterinary journal ]]> https://www.proactiveinvestors.com.au/companies/news/218804/cannpal-animal-therapeutics-rd-research-to-be-published-in-leading-veterinary-journal-218804.html CannPal Animal Therapeutics Ltd (ASX:CP1) is being recognised for its robust and leading research into medicinal cannabis treatments for animals through participation in Australia’s largest veterinary conference and publication of its first research abstract.

This will provide the company the opportunity to directly present to 1,400 veterinarians at the Australian Veterinary Association (AVA) Innovation, Research and Development Symposium in May.

CannPal will also reach more than 5,000 through publication of its abstract in the Australian Veterinary Journal (AVJ), which is Australia’s premier veterinary scientific journal.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

Founder and managing director Layton Mills said the presentation and AVJ publication was a significant milestone for the company.

He said: “There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.

“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines”.

“Building a trusting relationship” with vets

“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”

During the AVA Innovation Symposium in Perth next month CannPal’s head of R&D Dr Margaret Curtis will present on the company’s Phase 1 trial results.

This will include the pharmacokinetic, safety, gene expression and inflammatory biomarker results from the robust randomised three group parallel pharmacokinetic study completed in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The AVA event between May 5 and 10 is the largest veterinary conference in Australia, with an average of 1,400 veterinary professionals expected to attend.

It is a platform for industry and animal researchers to present their clinical research and findings directly to the veterinary profession.

The Innovation Symposium will be on Sunday, May 5, and Dr Curtis will present at 3.35pm alongside speakers from world-leading animal health companies such as Bayer, Ceva and Virbac.

Abstracts from the symposium will be published in the AVJ, which is Australia’s premier veterinary scientific journal, reaching an audience of over 5,000 AVA members.

CannPal generates “exciting results”

Dr Curtis said: “This is a great opportunity to get our initial results out into the veterinary fraternity in Australia.

“The AVJ is widely read, and publication of this work will further disseminate the exciting results that CannPal is generating, bringing us closer to potentially approvable cannabis-derived medicines for pets.”

MD Mills said: “Since founding the company, CannPal has placed diligent focus on building a credible and experienced R&D team to complete robust and world leading research on the safety and efficacy of cannabis-derived compounds for companion animals.

“The AVA Symposium is an opportunity for CannPal to start sharing some of that research with the scientific and veterinary community, in the hopes of establishing CannPal as a clear leader in this field.”

READ: CannPal Animal Therapeutics director buys 100,000 shares on-market

CannPal is researching and developing medicines derived from cannabinoids with the aim of providing veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

]]>
Thu, 18 Apr 2019 10:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/218804/cannpal-animal-therapeutics-rd-research-to-be-published-in-leading-veterinary-journal-218804.html
<![CDATA[News - CannPal Animal Therapeutics director buys 100,000 shares on-market ]]> https://www.proactiveinvestors.com.au/companies/news/216127/cannpal-animal-therapeutics-director-buys-100000-shares-on-market-216127.html CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive director Robert Johnston has purchased 100,000 shares through on-market trades.

The purchase amounted to $11,911.86 and increased Johnston’s total holding in the company to 300,000 shares.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

Last month, CannPal received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

]]>
Mon, 11 Mar 2019 08:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/216127/cannpal-animal-therapeutics-director-buys-100000-shares-on-market-216127.html
<![CDATA[News - CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market ]]> https://www.proactiveinvestors.com.au/companies/news/215668/cannpal-animal-therapeutics-sees-lucrative-opportunity-in-cannabinoids-based-animal-health-market-215668.html CannPal Animal Therapeutics Ltd (ASX:CP1) is well placed to benefit from the rapidly growing cannabinoids-based animal health market.

Focusing on animal well-being, particularly companion pets (e.g., cats and dogs) could be lucrative for the company.

According to the American Pet Product Association, annual pet industry expenditure in the U.S. has grown in each of the past 18 years, with Americans estimated to have spent $18.3 billion on veterinary care and $15.5 billion on supplies and over-the-counter medicines in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The company recently received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

Elixinol Global gaining traction in the pet space

Many players in the industrial hemp and cannabidiol (CBD) based dietary supplement market are seeing a growing market for their products catering to the pet industry.

This includes Elixinol Global Ltd (ASX:EXL), manufacturer of Edibites, a CBD pet treat specifically formulated for dogs.

Elixinol recently witnessed an increase in private label production which now accounts for around 40% of its U.S. revenue of $32.5 million in 2018, with one large customer in the pet space driving most of the private label growth.

Cannabinoids-based animal health is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.

]]>
Mon, 04 Mar 2019 13:57:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215668/cannpal-animal-therapeutics-sees-lucrative-opportunity-in-cannabinoids-based-animal-health-market-215668.html
<![CDATA[News - CannPal Animal Therapeutics receives approvals for two clinical studies ]]> https://www.proactiveinvestors.com.au/companies/news/214500/cannpal-animal-therapeutics-receives-approvals-for-two-clinical-studies-214500.html CannPal Animal Therapeutics Ltd (ASX:CP1) has received two key ethics approvals to progress the research and development of lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal’s phase IIa clinical study for CPAT-01 will see 60 dogs with osteoarthritis recruited from veterinary clinics across New South Wales and Queensland.

The clinical trial for DermaCann is an eight week efficacy study to explore effects and confirm safety and will see 45 dogs recruited.

CannPal hopes to complete recruitment for both studies by mid CY2019.

READ: CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase

CannPal's founder and managing director Layton Mills said: “I’m delighted that we’re moving into the second Phase for CPAT-01, within just a few months of completing our phase I research activities.

“I’m also pleased that our research and development team has been able to progress the DermaCann project plan with the same momentum via the initiation of our safety and efficacy study, which is a major milestone for our nutraceutical strategy.

“I’m looking forward to commencing our phase II pilot studies for CPAT-01 and the potential to explore commercialisation opportunities for our nutraceutical products in 2019.”

READ: CannPal Animal Therapeutics chairman buys company shares

Yesterday, CannPal’s non-executive chairman Geoff Starr purchased 80,000 shares in the company worth $10,193 via on-market trades.

]]>
Wed, 13 Feb 2019 12:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214500/cannpal-animal-therapeutics-receives-approvals-for-two-clinical-studies-214500.html
<![CDATA[News - CannPal Animal Therapeutics chairman buys company shares ]]> https://www.proactiveinvestors.com.au/companies/news/214490/cannpal-animal-therapeutics-chairman-buys-company-shares-214490.html CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive chairman Geoff Starr has purchased 80,000 shares in the company via on-market trades.

The $10,193 parcel is Starr’s first purchase of company shares and his first step to aligning himself with shareholders.

READ: CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

In the recent December quarterly report chairman Geoff Starr said: “I’m extremely happy with the progress that CannPal has made in the December quarter, and particularly the company’s progress with our nutraceutical program, while maintaining focus on our lead pharmaceutical.

“Our strategy has been to remain focused and diligent in the development of compliant animal health products and that work is beginning to pay off as we’re getting closer towards getting CannPal in a position to explore commercialisation opportunities in 2019.

“I’m looking forward to the team continuing with the same momentum throughout the new-year.”

]]>
Wed, 13 Feb 2019 08:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214490/cannpal-animal-therapeutics-chairman-buys-company-shares-214490.html
<![CDATA[News - CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase ]]> https://www.proactiveinvestors.com.au/companies/news/213454/cannpal-animal-therapeutics-well-capitalised-as-it-moves-towards-commercialisation-phase-213454.html CannPal Animal Therapeutics Ltd (ASX:CP1) intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The well-capitalised, Sydney-based company released its quarterly cashflow report and market update for December quarter 2018 earlier today.

READ: CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs

CannPal highlighted its $4.55 million cash balance at the end of the December quarter, comparing it with the $510,000 quarterly cash burn which had primarily related to its R&D costs.

During the quarter, the diligent budget manager received a $297,299 R&D tax refund from the Australian Government and attributed its increase in legal costs and fees in part to collecting the refund.

CannPal confirmed it was fully-funded up to its phase II pilot studies for CPAT-01 and other milestones it has communicated to market, including the commercialisation of its lead nutraceutical product DermaCann.

READ: CannPal Animal Therapeutics director shows faith in company through on-market purchase

CannPal founder and managing director Layton Mills told the market: “I am very excited about the progress that we’re making across our entire portfolio.

“Our work so far continues to build confidence that CannPal will be able to develop and commercialise compliant and evidence-based products for companion animals in the areas of pain and osteoarthritis, as well as skin and joint health.

“I’m looking forward to commencing our Phase 2 pilot studies for CPAT-01 and the potential to explore commercialisation opportunities for our nutraceutical products in 2019.”

CannPal chairman Geoff Star highlighted the team’s momentum, saying “I’m extremely happy with the progress that CannPal has made in the December quarter, and particularly the company’s progress with our nutraceutical program, while maintaining focus on our lead pharmaceutical.

“Our strategy has been to remain focused and diligent in the development of compliant animal health products and that work is beginning to pay off as we’re getting closer towards getting CannPal in a position to explore commercialisation opportunities in 2019.

“I’m looking forward to the team continuing with the same momentum throughout the new year.”

Phase II pilot studies

This quarter, the protocol for the highlighted first study in its phase II program, a phase 2A pilot clinical study of CPAT-01 in client-owned animals with the arthritic bone condition OA, is being worked on.

CannPal will draw on its results from phase I (A&B) studies completed last year, including its phase 1B study of CPAT-01 in more than 48 dogs completed last month, which evaluated the development drug for pain and inflammation control in dogs.

Gene expression studies have revealed clear cannabinoid impact in important pain and inflammatory pathways, supporting proposed pain and inflammatory control claims for CPAT-01.

A Melbourne-based integrated medical lab has been helping CannPal identify the drug’s effects on key chemokine and cytokines associated with the activated pain and inflammatory genes highlighted in the phase I studies.

A kick-off of the study is now expected in the June half-year 2019.

Neutraceutical products

On the nutraceuticals front, CannPal’s New Zealand-based manufacturing partner Jaychem Industries Ltd is also expected to start a canine study of DermaCann, which is being developed as a CBD (cannabidiol)-derived oral skin supplement for dogs.

Auckland-based Jaychem completed laboratory formulation work in the December quarter and will manufacture a batch of formula in the June half for the study, in a start to the formulation stability program.

NSW biotech CannPal will add the safety data from development work and the upcoming skin study results to a dossier for complementary animal health product approval (CAHP) with Australian Pesticides and Veterinary Medicines Australia (APVMA).

CAHP approval would allow animal owners in Australia to buy DermaCann through Australian veterinarians and would represent a significant milestone for the animal pharmaceuticals company.

READ: CannPal Animal Therapeutics caps off busy September quarter

CannPal also worked with the Australian Government’s independent science agency CSIRO last quarter, backed by a $500,000 CSIRO grant, and this is expected to generate additional commercialisation opportunities for CannPal.

The collaborators claimed success from their first phase of study in evaluating the feasibility of using CSIRO’s food-producing technologies to turn CannPal’s oil-based formulations into a powdered product.

CannPal hopes to identify opportunities to use the delivery mechanism for animal nutraceuticals in its pipeline.

Significant shareholders

The tightly-held company’s top 20 shareholders had 68.18% of the company on September 17, with The Trust Company (Australia) Limited <MOF A/C> leading the pack with a 15.8% stake.

CannPal’s other significant shareholders were Gemelli Nominees Pty Ltd, with 9.32%, Pepaanne Pty Ltd <The Chapman Family A/C> (8.23%), founder Layton Patrick Mills <DJS Family A/C> (7.39%) and Tania Maree Vidovic <Star V Family A/A> (7.39%).

 

]]>
Mon, 28 Jan 2019 19:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/213454/cannpal-animal-therapeutics-well-capitalised-as-it-moves-towards-commercialisation-phase-213454.html
<![CDATA[News - CannPal Animal Therapeutics director shows faith in company through on-market purchase ]]> https://www.proactiveinvestors.com.au/companies/news/212197/cannpal-animal-therapeutics-director-shows-faith-in-company-through-on-market-purchase-212197.html CannPal Animal Therapeutics Ltd (ASX:CP1) director Rob Clifford has demonstrated his confidence in the company’s unique strategy of developing cannabis-derived medications for animals by acquiring shares on-market.

Clifford, a non-executive director, this week purchased 50,000 shares for an indirect interest.

Through this interest, he now holds more than 480,000 shares, which at an intra-day high of 14 cents today was valued in excess of $67,200.

READ: CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs

Last month CannPal completed dosing for the phase 1B study of its lead drug candidate CPAT-01, which is being developed as a pain and inflammatory control for dogs.

More than 48 Beagles and Foxhounds were recruited for the study across various weights and ages with no adverse events reported in dogs across all treatment groups.

Gene expression studies so far have revealed clear cannabinoid impact in important pain and inflammatory pathways supporting the proposed pain and inflammatory control claims for CPAT-01.

READ: CannPal Animal Therapeutics director acquires further shares on-market

CannPal is now working with a Melbourne-based integrated medical laboratory to identify the drug’s effects on key chemokine and cytokines associated with the activated pain and inflammatory genes highlighted in the phase I studies.

The results of this in conjunction with the gene expression data will support the dose justification for CPAT-01 before commencing the clinical program.

Phase II study planned

CannPal has generated significant data on the pharmacokinetic and gene expression profiles of cannabinoids in dogs.

This will be used to begin protocol development for the first phase II study, a pilot dose determination study in client-owned animals with OA to clinically validate the effects seen in phase I studies.

The company aims to begin recruitment for this study during the current quarter.

Testing in cats

CannPal has also received ethics approvals to commence the testing of CPAT-01 in cats.

As cats represent over 25% of the companion animal drug market, there’s a clear unmet need for safe therapeutics that can be used long-term to treat pain and inflammation.

]]>
Wed, 09 Jan 2019 14:54:00 +1100 https://www.proactiveinvestors.com.au/companies/news/212197/cannpal-animal-therapeutics-director-shows-faith-in-company-through-on-market-purchase-212197.html
<![CDATA[News - CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs ]]> https://www.proactiveinvestors.com.au/companies/news/211004/cannpal-animal-therapeutics-concludes-successful-phase-1b-cannabinoid-study-in-dogs-211004.html CannPal Animal Therapeutics Ltd (ASX:CP1) has successfully completed dosing for the phase 1B study of its lead drug candidate CPAT-01, being developed as a pain and inflammatory control for dogs.

More than 48 Beagles and Foxhounds were recruited for the study across various weights and ages.

Importantly, no adverse events were reported in dogs across all treatment groups.

READ: CannPal Animal Therapeutics caps off busy September quarter

The gene expression studies so far have revealed clear cannabinoid impact in important pain and inflammatory pathways supporting the proposed pain and inflammatory control claims for CPAT-01.

CannPal is now working with a Melbourne-based integrated medical laboratory to identify the drug’s effects on key chemokine and cytokines that are associated with the activated pain and inflammatory genes highlighted in the phase I studies.

The results of this in conjunction with the gene expression data will support the dose justification for CPAT-01 prior to commencing the clinical program.

READ: CannPal Animal Therapeutics director acquires further shares on-market

CannPal founder and managing director Layton Mills said: “I am very pleased at the speed in which we are progressing through the CPAT-01 development plan, but more importantly, the significant amounts of data we are collecting along the way.

“Our vision is to be one of the first animal health companies to provide veterinarians with GMP produced and regulatory approved cannabinoid-derived therapeutics for pets.

“We have been strict on resources and strong on creativity to ensure we remain well capitalised to continue with the development of CPAT-01 in 2019, which wouldn’t be possible without the help and support of our experienced research partners.”

Phase II study protocol development

The company has now generated significant data on the pharmacokinetic and gene expression profiles of cannabinoids in dogs.

This data will be used to commence the protocol development for the first phase II study, a pilot dose determination study in client-owned animals with osteoarthritis to clinically validate the effects seen in phase I studies.

CannPal is aiming to commence recruitment for this study in Q1 2019.

CPAT-01C cat study

The company has also received ethics approvals to commence the testing of CPAT-01 in cats.

Cats represent over 25% of the companion animal drug market and there’s a clear unmet need for safe therapeutics that can be used long-term to treat pain and inflammation in felines.

Over 20 cats have been recruited for the study across varying weights and ages.

The animal phase of the study was originally planned for Q4 2018 but is now expected to commence early in 2019 across multiple research sites.

]]>
Wed, 12 Dec 2018 08:46:00 +1100 https://www.proactiveinvestors.com.au/companies/news/211004/cannpal-animal-therapeutics-concludes-successful-phase-1b-cannabinoid-study-in-dogs-211004.html
<![CDATA[News - CannPal Animal Therapeutics director acquires further shares on-market ]]> https://www.proactiveinvestors.com.au/companies/news/209622/cannpal-animal-therapeutics-director-acquires-further-shares-on-market-209622.html CannPal Animal Therapeutics Ltd (ASX:CP1) director Max Johnston has shown confidence in the company’s development of cannabis-derived medications for animals by acquiring shares on-market.

Johnson, a non-executive director, has this week acquired more than 35,600 shares with a total value of almost $5,000.

READ: CannPal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications

This takes the total number of shares held in indirect interest to 200,000 shares.

Last month Johnston acquired almost 64,400 shares with a total value of more than $9,000.

READ: CannPal Animal Therapeutics caps off busy September quarter

CannPal had a busy September quarter entering two research agreements and advancing its lead cannabis-derived drug candidate CPAT-01.

CPAT-01D, a pain treatment for dogs, received ethics approvals and the CPAT-01 development program was expanded to include cats - CPAT-01C.

48 beagles and foxhounds enrolled

The phase Ib study for CPAT-01D is underway and the live phase is expected to be completed by the end of this quarter.

This study has enrolled 48 beagles and foxhounds of both sexes in wide weight and age ranges after clinical screening and examination.

At September 30 the company had a cash balance of $4.72 million, which was in line with budget forecasts and sufficient to continue with its research and development activities in subsequent months.

READ: CannPal Animal Therapeutics’ sponsor fee for lead animal drug candidate waived by US FDA

CannPal was founded by a team of experienced executives to establish a new standard of care in animal health by providing veterinarians with regulatory approved, Cannabinoid-based pharmaceuticals.

The company has identified an opportunity to develop first-in-class medicines for cats, dogs and horses, derived from the cannabis plant.

]]>
Wed, 21 Nov 2018 09:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209622/cannpal-animal-therapeutics-director-acquires-further-shares-on-market-209622.html
<![CDATA[News - CannPal Animal Therapeutics caps off busy September quarter ]]> https://www.proactiveinvestors.com.au/companies/news/207606/cannpal-animal-therapeutics-caps-off-busy-september-quarter-207606.html CannPal Animal Therapeutics Ltd (ASX:CP1) has had a busy September quarter entering two research agreements and advancing its lead cannabis-derived drug candidate CPAT-01.

CPAT-01D, a pain treatment for dogs, received ethics approvals and the CPAT-01 development program was expanded to include cats CPAT-01C.

The phase Ib study for CPAT-01D has commenced and is expected to be completed this December quarter.

READ: CannPal Animal Therapeutics commences dog pain control study

CannPal's managing director Layton Mills said: “This has been another important quarter for CannPal with some significant milestones.

“Our additional research agreements are further validation of the high-quality research we are undertaking in our mission to develop cannabis-derived treatments for companion animals.

“In addition, the rapid progression of our clinical studies and development of our nutraceutical pipeline underscore our commitment to delivering value to our shareholders.”

Solid end-of-quarter cash balance

CannPal had a cash balance of $4.72 million in line with its budget forecasts and sufficient to continue with its research and development activities in the coming months.

READ: CannPal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications

Earlier this month, director Max Johnston demonstrated his confidence in the company’s cannabis-derived medications for animals by acquiring shares on-market.

Johnston, a non-executive director, acquired almost 64,400 shares with a total value of more than $9,000.

]]>
Tue, 23 Oct 2018 07:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/207606/cannpal-animal-therapeutics-caps-off-busy-september-quarter-207606.html
<![CDATA[News - Cannpal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications ]]> https://www.proactiveinvestors.com.au/companies/news/206536/cannpal-animal-therapeutics-director-shows-confidence-in-companys-cannabis-derived-animal-medications-206536.html CannPal Animal Therapeutics Ltd (ASX:CP1) director Max Johnston has demonstrated his confidence in the company’s cannabis-derived medications for animals by acquiring shares on-market.

Johnston, a non-executive director, has acquired almost 64,400 shares with a total value of more than $9,000.

This takes the total number of shares held in indirect interest to almost 164,400 shares.

READ: CannPal Animal Therapeutics’ sponsor fee for lead animal drug candidate waived by US FDA

CannPal was recently granted a second US Food and Drug Administration (FDA) sponsor fee waiver for its lead drug candidate CPAT-01, an innovative cannabis-derived pain control for cats and dogs.

The waiver was granted under the significant barrier to innovation provision of the FDA’s Animal Drug User Fee Act (ADUFA) of 2003.

The waiver covers the current US$75,150 FY18 ADUFA sponsor fee which can be renewed each US fiscal year.

FDS waiver applies to CPAT-01

CannPal may also be eligible for reductions in other fees such as the drug application fee which can cost in excess of US$300,000.

The company was initially granted a fee waiver for an osteosarcoma pain treatment under the Minor Use/Minor Species (MUMS) pathway in 2017 which is a pathway that applies to diseases that affect a minor number of patients every year.

This new waiver under the barrier to innovation pathway is applicable to much broader indications, which allows CannPal to apply the waiver to CPAT-01D, which is being developed as a pain control in dogs.

READ: CannPal Animal Therapeutics commences dog pain control study

CannPal is undertaking a phase Ib study for CPAT-01D with 48 beagles and foxhounds of both sexes in wide weight and age ranges enrolled after clinical screening and examination.

The live phase of the study is expected to be completed late in this quarter.

CannPal was founded by a team of experienced executives to establish a new standard of care in animal health by providing veterinarians with regulatory approved, Cannabinoid-based pharmaceuticals.

The company has identified an opportunity to develop first-in-class medicines for cats, dogs and horses, derived from the cannabis plant.

]]>
Mon, 08 Oct 2018 14:05:00 +1100 https://www.proactiveinvestors.com.au/companies/news/206536/cannpal-animal-therapeutics-director-shows-confidence-in-companys-cannabis-derived-animal-medications-206536.html
<![CDATA[News - CannPal Animal Therapeutics’ sponsor fee for lead animal drug candidate waived by US FDA ]]> https://www.proactiveinvestors.com.au/companies/news/205489/cannpal-animal-therapeutics-sponsor-fee-for-lead-animal-drug-candidate-waived-by-us-fda-205489.html CannPal Animal Therapeutics Ltd (ASX:CP1) has been granted its second US FDA (Food and Drug Administration) sponsor fee waiver for its lead drug candidate CPAT-01.

CPAT-01 is an innovative cannabis-derived pain control for cats and dogs.

"Because pets are family too" #medicalcannabis #animalhealth #cannpal pic.twitter.com/ncPwm217Lg

— CannPal (@CannPalAT) July 17, 2017

The waiver was granted under the significant barrier to innovation provision of the FDA’s Animal Drug User Fee Act (ADUFA) of 2003.

The waiver covers the current US$75,150 FY18 ADUFA sponsor fee which can be renewed each US fiscal year.

CannPal may also be eligible for reductions in other fees such as the drug application fee which can cost in excess of US$300,000.

READ: CannPal Animal Therapeutics commences dog pain control study

The company was initially granted a fee waiver for an osteosarcoma pain treatment under the Minor Use/Minor Species (MUMS) pathway in 2017 which is a pathway that applies to diseases that affect a minor number of patients every year.

This new waiver under the barrier to innovation pathway is applicable to much broader indications, which allows CannPal to apply the waiver to CPAT-01D, which is being developed as a pain control in dogs.

CannPal plans to take the results from the recently commenced phase 1A and B studies to file an INAD (Investigational New Animal Drug) application with the FDA prior to the AU FY19 financial year, at which point the sponsor fee would be required to be paid.

READ:  CannPal Animal Therapeutics positioned in a growing animal health market

CannPal founder and managing director Layton Mills said: “Receiving this fee waiver not only provides additional cost savings for the company but also further validates our focus on following regulatory protocol and seeking added value opportunities for our shareholders.

“The phase 1B study is now well underway and we are looking forward to continuing on our path of developing safe and scientifically-proven treatments for companion animals.”

]]>
Mon, 24 Sep 2018 12:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205489/cannpal-animal-therapeutics-sponsor-fee-for-lead-animal-drug-candidate-waived-by-us-fda-205489.html
<![CDATA[News - CannPal Animal Therapeutics commences dog pain control study ]]> https://www.proactiveinvestors.com.au/companies/news/204014/cannpal-animal-therapeutics-commences-dog-pain-control-study-204014.html CannPal Animal Therapeutics Ltd (ASX:CP1) has commenced its phase Ib study for its lead drug candidate CPAT-01D, a cannabis-derived pain control for dogs.

48 beagles and foxhounds of both sexes in wide weight and age ranges have been enrolled after clinical screening and examination.

The live phase of the study is expected to be completed late in the coming December quarter 2018.

READ: CannPal Animal Therapeutics receives approval to advance clinical studies

CannPal's managing director Layton Mills said: “It is excellent to see the significant progress we are making with CPAT-01, and the quick turn-around time between phase Ia and phase IIb.

“CPAT-01 has the potential to offer a new solution for dogs that suffer from painful conditions and we look forward to rapidly progressing through phase II of this exciting research, at the completion of our phase I studies.”

Phase Ib is a continuation of the pharmacokinetic and safety study which started earlier in 2018 and showed excellent safety and tolerability for CPAT-01.

It builds on the pilot data already generated and includes additional endpoints.

Preparing for an application the FDA

With the results from these phase Ia and Ib studies, Cannpal plans to prepare to file an Investigational New Animal Drug (INAD) application with the US Food and Drug Administration (FDA).

It will also begin designing the protocol for the company’s pilot dose determination study to commence in the June half of 2019, which will include client-owned animals with osteoarthritis.

READ: CannPal Animal Therapeutics teams up with University of Melbourne

Last month, CannPal entered into a memorandum of understanding (MoU) with the University of Melbourne to research an epilepsy treatment for dogs.

Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol treatment for epilepsy in dogs in 2019.

]]>
Mon, 03 Sep 2018 11:53:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204014/cannpal-animal-therapeutics-commences-dog-pain-control-study-204014.html
<![CDATA[News - CannPal Animal Therapeutics teams up with University of Melbourne ]]> https://www.proactiveinvestors.com.au/companies/news/202423/cannpal-animal-therapeutics-teams-up-with-university-of-melbourne-202423.html CannPal Animal Therapeutics Ltd (ASX:CP1) has entered into a memorandum of understanding (MoU) with the University of Melbourne to research an epilepsy treatment for dogs.

Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol (CBD) treatment for epilepsy in dogs in 2019.

The MoU builds on CannPal’s current research pipeline which includes the phase Ib study for CPAT-01, a pain control in dogs, and its extension CPAT-01C for cats.

READ:  CannPal Animal Therapeutics receives approval to advance clinical studies

CannPal's managing director Layton Mills said: “This MoU with the University of Melbourne is the latest in a long line of strategic agreements CannPal has entered, to establish the company as a global leader in cannabinoid-derived therapeutics for companion animals.

“It’s further validation of the high-quality research we are undertaking and we look forward to working with the University on this project.”

Cannabidiol has a number of reported health benefits

Cannabidiol is a non-psychoactive compound derived from cannabis with a number of reported health benefits which include anxiolytic, anti-inflammatory, antibacterial and antiseizure properties.

In June 2018, the US Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy in human patients of 2 years of age and older.

This is the first FDA-approved drug that contains a purified drug substance derived from marijuana and the Company is hopeful that similar effects using cannabinoids can be seen in dogs with idiopathic epilepsy.

]]>
Wed, 08 Aug 2018 10:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202423/cannpal-animal-therapeutics-teams-up-with-university-of-melbourne-202423.html
<![CDATA[News - CannPal Animal Therapeutics receives approval to advance clinical studies ]]> https://www.proactiveinvestors.com.au/companies/news/202049/cannpal-animal-therapeutics-receives-approval-to-advance-clinical-studies-202049.html CannPal Animal Therapeutics Ltd (ASX:CP1) has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain control in dogs.

Phase Ib is a continuation of research into CPAT-01, an innovative cannabis-derived pain control being developed for both cats and dogs.

Set to commence this month, phase Ib of the pharmacokinetic and safety study has recruited 48 dogs for the study.

READ: CannPal Animal Therapeutics positioned in a growing animal health market

CannPal's managing director Layton Mills said: “We’re very pleased to have received ethics approval for our phase Ib study for CPAT-01.

“The speed with which CannPal has moved to the next stage of our research is indicative of our commitment to progressing our clinical development plans on time.

“We look forward to further updating the market on the results of this study, which are expected in Q3 2018.”

Study also assessing tolerability

The study design will be assessing additional pharmacokinetic and safety parameters, including tolerability at five times the estimated dose, and early dose ranging confirmation.

The company is also evaluating the cannabinoid impact on identified gene expression targets to identify underlying mechanisms of action.

]]>
Thu, 02 Aug 2018 09:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202049/cannpal-animal-therapeutics-receives-approval-to-advance-clinical-studies-202049.html
<![CDATA[News - CannPal Animal Therapeutics positioned in a growing animal health market ]]> https://www.proactiveinvestors.com.au/companies/news/200893/cannpal-animal-therapeutics-positioned-in-a-growing-animal-health-market-200893.html CannPal Animal Therapeutics Ltd (ASX:CP1) is leveraged to the growing US$31 billion global animal health industry.

The pharmaceutical-focused animal health company is researching the benefits of medical cannabis for companion animals.

CannPal is primarily focused on the development of canine pain medication CPAT-01D, while developing a strong pipeline of other animal pharmaceutical and nutraceutical products.

Completed phase Ia study

During the June quarter 2018, CannPal completed phase Ia of the pharmacokinetic and safety study for CPAT-01, CannPal’s lead drug candidate targeting pain in dogs.

All observational endpoints of the phase Ia study were met.

The initial target dose had an excellent safety profile with no adverse events observed at the dosages administered.

Progressing to phase Ib

CPAT01 showed significant absorption in its current formulation and the success of phase Ia allowed the company to progress into the preparation of the phase Ib study.

Phase Ib is expected to commence in the September quarter and will include 48 dogs of mixed age, sex and breed.

READ: CannPal Animal Therapeutics to research a cannabis-derived pain treatment for cats

Following the success of phase Ia, CannPal expanded the development program for CPAT-01 to include cats through a research agreement with Eurofins Animal Health Pty Ltd.

The two companies aim to develop a cannabis-derived pain treatment for cats at Eurofins’ research facility in New South Wales.

CPAT-01C (C denotes cats) will leverage knowledge gained from the CPAT-01D (D denotes dogs) studies.

Fully funded for phase II

With $5.11 million in cash at the end of the June quarter 2018, CannPal is fully funded for the planned phase II development of CPAT-01D.

Phase IIa pilot dose determination and population pharmacokinetic studies aim to commence in the December quarter of this year.

CPAT-01D is a pain medication for dogs

CPAT-01D has been developed using active ingredients (both THC and CBD) from the cannabis plant to target symptoms of pain in dogs.

The global canine anti-inflammatory products market has an estimated market size of over US$1 billion.

CPAT-01D is a cost-effective, safe alternative to existing pain medication for dogs with less side effects.

There are little to no pain medications approved for companion animals that are suitable for safe long-term use and non-steroidal anti-inflammatory drugs NSAIDs are widely known for negative side effect profiles.

READ: Cannpal Animal Therapeutics Ltd working with CSIRO in developing cannabinoid treatments for animals

CannPal is also developing nutraceuticals using compounds from the less regulated hemp plant, as part of an early revenue generation strategy.

During the June quarter 2018, CannPal entered into a manufacturing agreement with JayChem Industries Ltd to commence the development work for DermaCann, a treatment for canine skin health.

DermaCann is the first of CannPal’s nutraceutical range and is expected to be market ready as early as mid-2019.

CannPal’s strategy is to position DermaCann as a provider of early potential revenues through alternative regulatory pathways.

]]>
Tue, 17 Jul 2018 09:56:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200893/cannpal-animal-therapeutics-positioned-in-a-growing-animal-health-market-200893.html
<![CDATA[News - CannPal Animal Therapeutics to research a cannabis-derived pain treatment for cats ]]> https://www.proactiveinvestors.com.au/companies/news/200077/cannpal-animal-therapeutics-to-research-a-cannabis-derived-pain-treatment-for-cats-200077.html CannPal Animal Therapeutics Ltd (ASX:CP1) will work with veterinary research organisation Eurofins Animal Health Pty Ltd to develop a cannabis-derived pain treatment for cats.

The two companies have entered into a research services agreement which will see Eurofins design and facilitate pilot studies in cats at its research facility in New South Wales.

READ: CannPal Animal Therapeutics achieves milestone in Phase 1A study

CannPal recently completed Phase 1A of a Pharmacokinetic and Safety Study for CPAT-01, the company’s lead drug candidate being developed as a pain control for dogs.

The promising safety profile has given management the confidence to expand the development program to include cats (CPAT-01C) as a pain control for felines.

CannPal’s founder and managing director Layton Mills said: “We’re delighted to announce a research collaboration with Eurofins to expand the development program of CPAT-01 into cats.

“We believe that there’s a significant unmet need for a feline pain treatment with a more desirable safety profile.”

 

The agreement will see Eurofins prepare and submit ethics applications for study clearance.

It will be responsible for fulfilling associated ethics reporting requirements and carrying out the animal’s phase of the research.

READ: Cannpal Animal Therapeutics Ltd working with CSIRO in developing cannabinoid treatments for animals

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used treatment for pain in cats, yet only two NSAID’s have been approved for use by the FDA in the USA.

None have been approved for long-term use due to potential side effects and toxicities.

Alternative solution to treat cats

CannPal hopes that CPAT-01C can offer an alternative solution to help treat pain in cats in a safe and ethical way.

Mills said: “I strongly feel that this opportunity can create added value for our shareholders.”

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

Eurofins supports animal health industry

Eurofins is a leader in food, environment and pharmaceutical products testing and in agroscience and veterinary research services that support the global animal health industry.

It conducts preclinical and clinical studies to GCP and GLP standards, compliant with regulatory requirements, and serve as an ideal partner to commence CannPal’s research on pain treatment for cats.

Technical activities involve the conduct of clinical field, pen and laboratory studies to determine the safety and efficacy of new products designed to improve animal health and welfare.

]]>
Wed, 04 Jul 2018 09:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200077/cannpal-animal-therapeutics-to-research-a-cannabis-derived-pain-treatment-for-cats-200077.html
<![CDATA[News - Cannpal Animal Therapeutics Ltd working with CSIRO in developing cannabinoid treatments for animals ]]> https://www.proactiveinvestors.com.au/companies/news/199729/cannpal-animal-therapeutics-ltd-working-with-csiro-in-developing-cannabinoid-treatments-for-animals-199729.html CannPal Animal Therapeutics Ltd (ASX:CP1) will work with CSIRO to research the use of food production technologies to enhance delivery of cannabis-derived therapeutic formulations in animals.

The company has entered a research agreement with the national science agency under its Kick-Start initiative for eligible Australian small to medium enterprises (SMEs).

CannPal will receive dollar-matched funding to contribute towards an eligible collaborative research project with CSIRO researchers.

READ: CannPal Animal Therapeutics achieves milestone in Phase 1A study

Founder and managing director Layton Mills said: “We are very pleased to have received this funding voucher as part of our research agreement with the CSIRO.

“Our vision is to be a global leader in cannabinoid-derived therapeutics.

“Through this research agreement, we’re confident that we can develop added value that can significantly advance the development of our therapeutic platform.”

 

CannPal is developing a range of cannabis-based therapeutic products targeting companion animals.

Focus on DermaCann

Its focus is on DermaCann, a nutraceutical targeting canine skin health, and CPAT-01 in development as a veterinary medicine for pain in dogs.

Under the new initiative, CSIRO and CannPal will undertake initial research into formulation work.

CannPal intends to further develop new and existing delivery systems to create proprietary

formulations of the company’s therapeutic products.

The company’s management believes this work could provide a significant competitive advantage.

A Kick-Start for businesses

CSIRO Kick-Start was launched in April 2017 and provides innovative Australian start-ups and SMEs with funding support and access to CSIRO’s research expertise and facilities.

The program offers eligible businesses access to dollar-matched funding vouchers of $10,000-$50,000 to undertake the following research activities with CSIRO:

- Research into a new idea with commercial potential,

- Development of a novel or improved product or process, or

- The testing of a novel product or material developed by the business.

Innovative therapeutics

CannPal is researching and developing medicines derived from cannabinoids to provide

veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

The company has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant.

It is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that meet regulatory approval and support the health and well-being of companion animals.

]]>
Thu, 28 Jun 2018 10:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199729/cannpal-animal-therapeutics-ltd-working-with-csiro-in-developing-cannabinoid-treatments-for-animals-199729.html
<![CDATA[Media files - CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9681/cannpal-animal-therapeutics-leveraged-to-lucrative-potential-of-growing-market-9681.html Mon, 25 Jun 2018 10:38:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9681/cannpal-animal-therapeutics-leveraged-to-lucrative-potential-of-growing-market-9681.html <![CDATA[News - CannPal Animal Therapeutics achieves milestone in Phase 1A study ]]> https://www.proactiveinvestors.com.au/companies/news/198991/cannpal-animal-therapeutics-achieves-milestone-in-phase-1a-study-198991.html CannPal Animal Therapeutics Ltd (ASX:CP1) holds a unique position in the market researching the benefits of medical cannabis for companion animals.

CannPal aims to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

The company has now successfully completed Phase 1A of the Pharmacokinetic and Safety Study for CPAT-01 with all endpoints being met.

CPAT-01 is the company’s lead pharmaceutical in development as a pain control for dogs.

The formulations used in the study were well tolerated, with no adverse events reported, and significant absorption of the actives observed in the drug plasma concentration analysis.

Layton Mills, managing director, commented:

"The success of CannPal’s first live phase study is a significant milestone for the company as it shows we are capable of setting and hitting research milestones to drive shareholder value."

Next steps for CannPal

The success of Phase 1A has allowed to company to move forward with preparation for Phase 1B of the study, with 48 dogs enrolled.

CannPal is in the process of finalising the protocol for this study which is expected to commence in the September quarter 2018.

Mills added: "We are looking forward to commencing Phase 1B of this study and expanding the market potential of CPAT-01 with research into cats, a significantly unmet need in the companion animal drug market."

Opportunity

Cats share in almost 30% of the veterinary pain market and there’s a significant unmet need for safe feline pain treatments.

There are only two NSAID’s (Non-steroidal anti-inflammatory drugs) approved to treat pain in cats in the United States, and none for long term use.

CannPal enters into manufacturing agreement

Last month the company entered into a manufacturing agreement with New Zealand based veterinary contract manufacturing organisation, Jaychem Industries Ltd.

Jaychem is a privately owned GMP (Good Manufacturing Processes) contract manufacturer of a comprehensive range of innovative products including veterinary health products for livestock and companion animals, and serves as an ideal partner to provide GMP-quality contract manufacturing services for the company’s lead nutraceutical product, DermaCann.

DermaCann is being developed as a regulatory approved novel oral formulation to target canine skin health, expected to be ready for commercialisation in 2019.

READ: CannPal non-deal roadshow presentation ]]>
Mon, 18 Jun 2018 13:34:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198991/cannpal-animal-therapeutics-achieves-milestone-in-phase-1a-study-198991.html
<![CDATA[News - CannPal Animal Therapeutics delivers a medical cannabis milestone ]]> https://www.proactiveinvestors.com.au/companies/news/197776/cannpal-animal-therapeutics-delivers-a-medical-cannabis-milestone-197776.html CannPal Animal Therapeutics Limited (ASX:CP1) has achieved a milestone in entering into a manufacturing agreement with New Zealand based veterinary contract manufacturing organisation, Jaychem Industries Ltd.

The agreement will allow CannPal to proceed with developing DermaCann, a high-quality cannabinoid derived therapeutic that is targeted to meet GMP (Good Manufacturing Processes) standards.

The company has now commissioned pharmaceutical quality assurance and GMP compliance consultants, Seer Pharma, to perform a GMP Inspection of Jaychem to relevant standards that will apply to Dermacann in the company’s target regions.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

The core strategy is to use compounds derived from cannabis that have been de-risked in clinical humans studies, to progress straight into animal clinical trials.

]]>
Tue, 29 May 2018 10:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197776/cannpal-animal-therapeutics-delivers-a-medical-cannabis-milestone-197776.html
<![CDATA[News - CannPal Animal Therapeutics granted medical cannabis permit ]]> https://www.proactiveinvestors.com.au/companies/news/186576/cannpal-animal-therapeutics-granted-medical-cannabis-permit-186576.html CannPal Animal Therapeutics Ltd (ASX:CP1) has been granted an authorisation to possess and supply cannabis for scientific research by the New South Wales Ministry of Health.

The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985.

Importantly, the permit allows CannPal to apply for permits to import cannabis for the clinical trials planned for Q1 CY18.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals.

The company listed on the ASX in October 2017 after raising $6 million at an issue price of $0.20 per share.

CannPal has been working closely with Invetus, Australasia’s largest veterinary research organisation, to facilitate the importation of cannabis for scientific research in companion animals.

CannPal’s agreement with Invetus allows the company to store and research its prohibited substances at a secure purpose-built animal health research facility.

The cannabis oils being imported are for the company’s pharmacokinetic and safety studies scheduled for Q1 CY18.

The University of Queensland will be providing bioanalytical services for the studies with the results anticipated in Q2 CY18.

]]>
Thu, 02 Nov 2017 08:23:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186576/cannpal-animal-therapeutics-granted-medical-cannabis-permit-186576.html